List view / Grid view
In this Q&A, Revolo Biotherapeutics’ CEO, Woody Bryan, discusses how ‘1104, the Company’s lead candidate for allergic diseases, shifts the immune system from a pro-inflammatory state to a homeostatic state, offering potential remission for allergic conditions. We delve into its unique mechanism of action, supported by preclinical and clinical findings.…
The mRNA vaccine candidate more effectively limited symptoms and disease duration in non-human primates.
Researchers found that HD can impair early brain development through defects associated with mitochondrial dysfunction.
NpG-D-PSMA has shown great potential for targeted alpha therapy to combat prostate cancer.
The findings could aid the design of more stable drugs and improve the understanding of diseases linked to peptide aggregation.
RENAISSANCE can quantify unknown intracellular metabolic states, including metabolic fluxes.
The nucleic acid drug, iSN04, could have applications for pathological angiogenesis involved in atherosclerosis, cancer, and retinopathy.
The humanised antibody, Hv1Lt1, showed promising results in pancreatic cancer mouse models.
Vittoria Biotherapeutics is pioneering a novel form of CAR-T therapy for T-cell lymphoma using CRISPR gene editing. Here, co-founders Nicholas Siciliano and Marco Ruella explain how their approach promises to overcome tumour resistance, while also offering hope for new ways to treat solid cancers.
This study is first to demonstrate with statistical certainty that human visceral adipose tissue accumulated in the abdominal cavity secretes more extracellular vesicles.
Resolution Therapeutics is pioneering a novel approach to the treatment of chronic liver disease – by engineering the patient’s own macrophages to include regenerative properties. Cliff Brass, Chief Medical Officer at Resolution Therapeutics, explains how the aim is to reduce inflammation, improve liver function, and ultimately eliminate the need for…
Targeting the epigenetic states of specific retroelements in the human genome could mitigate the biological effects of ageing.
Tune into this episode where we investigate how antibody drug conjugates can be optimised, as well as the future of the field.
A new class of RNAs packed into extracellular vesicles have potential as biomarkers for prostate cancer and other diseases.
Researchers have developed a new AI tool which recognises that protein behaviour can vary by cell and by tissue type.
